How many GLP-1 import shipments has FDA refused, and from which countries?
How many GLP-1 drug shipments has FDA refused at import, and from which countries?
FDA’s import refusal files list 717 refused shipment lines whose FDA product code names semaglutide, tirzepatide, liraglutide, retatrutide or GLP-1, dated Jun 16, 2023 to Oct 30, 2026, the earliest in files that go back to Jan 1, 2002. The most came from Canada (251), Denmark (149) and United States (59). The charge FDA cited most often is “UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).” (617 lines).
Records read Nov 15, 2026. Each row is one refused line on an import entry, so one shipment with several products counts once per line. The country is the declared manufacturer’s country in FDA’s file.
By country
| Canada | 251 |
| Denmark | 149 |
| United States | 59 |
| China | 42 |
| United Kingdom | 42 |
| India | 32 |
| Colombia | 19 |
| Italy | 13 |
| Mexico | 13 |
| Japan | 11 |
| Bangladesh | 10 |
| Brazil | 9 |
| France | 9 |
| Netherlands | 7 |
| Turkey | 7 |
| Germany | 6 |
| Vietnam | 6 |
| Hong Kong | 5 |
| Singapore | 4 |
| Lithuania | 3 |
| Switzerland | 3 |
| Israel | 2 |
| Nigeria | 2 |
| Philippines | 2 |
| Albania | 1 |
| Australia | 1 |
| Bulgaria | 1 |
| Egypt | 1 |
| Greece | 1 |
| Honduras | 1 |
| Indonesia | 1 |
| Paraguay | 1 |
| Poland | 1 |
| Portugal | 1 |
| United States Outlying Islands | 1 |
By drug named in the product code
| Semaglutide | 501 |
| Tirzepatide | 201 |
| Retatrutide | 11 |
| Liraglutide | 4 |
By year
| 2023 | 54 |
| 2024 | 207 |
| 2025 | 303 |
| 2026 | 153 |
By form, per Import Alert 66-80
| Code not listed on Import Alert 66-80 | 685 |
| Active Pharm Ingred/Chems for Rx Compounding | 17 |
| NonSterile Powder | 7 |
| Sterile Powder | 6 |
| Active Pharm Ingred/Chems for Further Manuf | 2 |
FDA charges cited
A line can carry several charges. Text is FDA’s charge statement, verbatim.
| UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 617 |
| NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). | 144 |
| FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | 52 |
| DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | 20 |
| LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. | 10 |
| NO ENGLISH: Required label or labeling appears to not be in English in violation of 21 C.F.R. 201.15(c)(1). | 8 |
| DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient. | 6 |
| NO ENGLISH: Required label or labeling appears to not be in English in violation of 21 C.F.R. 801.15(c)(1) | 5 |
| INCONSPICU: Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. | 5 |
| WARNINGS: It appears to lack adequate warning against use in a pathological condition or by children where it may be dangerous to health or against an unsafe dose, method, administering duration, application, in manner/form, to protect users. | 5 |
| RX LEGEND: The article appears to be a prescription drug without a prescription drug legend as required by Section 503(b)(4). | 5 |
| 708NODIR A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears to lack adequate directions for use. | 5 |
| RXLABEL: The labeling fails to bear, at a minimum, the symbol 'RX Only'. | 4 |
| FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading. | 4 |
| 708NOREG A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act. | 4 |
| 708LIST A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears to not be included in a list required by section 510(j). | 4 |
| 708LBLFR A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears in a package form to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. | 3 |
| FALSE: The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(a)(1 ) of the FD&C Act in that the labeling is false or misleading in any particular. | 2 |
| NUTRIT LBL: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded in that the label or labeling fails to bear the required nutrition information. | 2 |
| AGR RX: The article appears to be a prescription drug manufactured in the U.S. and offered for import by other than the manufacturer and reimportation does not appear to have been authorized by the Secretary for use in a medical emergency. | 1 |
| DRUG GMPS: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the methods used in and controls used for the manufacture, processing, packing, or holding of drugs and other products do not appear to conform to current good manufacturing practices within the meaning of Section 501(a)(2)(B). | 1 |
| RXCOMPOUND: the labeling fails to bear, at a minimum, the symbol 'Rx only.' | 1 |
| LACKS N/C: The article is in package form and appears to not have a label containing an accurate statement of the quantity of the contents in terms of weight, measure or numerical count and no variations or exemptions have been prescribed by regs. | 1 |
| 708NOENG A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears that the required label or labeling to not be in English in violation of 21 C.F.R. 201.15(c)(1). | 1 |
| 708NORX A: The article is subject to refusal and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears to be a prescription drug but does not include the symbol 'Rx only' on its label. | 1 |
| 708NEWDR A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears to be an unapproved new drug. | 1 |
Most recent refused lines
| FDA refusal charges | Shipment ID | |||||
|---|---|---|---|---|---|---|
| Oct 30, 2026 | NOVO NORDISK | Canada | 61PCK72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 1FX-8781355-7/10003/1 |
| Oct 29, 2026 | Name not shown | Italy | 61PCY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | SCS-5299095-7/10003/1 |
| Oct 14, 2026 | Name not shown | France | 61PCY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | SCS-5123290-6/10003/1 |
| Oct 13, 2026 | UAB LABOCHEMA LT | Lithuania | 61PIP78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 708NOREG A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act. 708LIST A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears to not be included in a list required by section 510(j). | 1FX-0240047-2/10002/1A |
| Oct 7, 2026 | SHANGHAI SHUNYI TRADE CO LTD | China | 61PIR74 TIRZEPATIDE (ANTI-DIABETIC) | NonSterile Powder | LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient. | XXX-0763321-9/1/1 |
| Oct 7, 2026 | SHANGHAI SHUNYI TRADE CO LTD | China | 61PIR78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. INCONSPICU: Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. WARNINGS: It appears to lack adequate warning against use in a pathological condition or by children where it may be dangerous to health or against an unsafe dose, method, administering duration, application, in manner/form, to protect users. DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient. | XXX-0763321-9/1/2 |
| Oct 7, 2026 | XU LIHUA JINGFANG Trading Co. LTD | China | 61PIR78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. INCONSPICU: Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. WARNINGS: It appears to lack adequate warning against use in a pathological condition or by children where it may be dangerous to health or against an unsafe dose, method, administering duration, application, in manner/form, to protect users. DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient. | XXX-0763336-3/1/1 |
| Oct 7, 2026 | XU LIHUA JINGFANG Trading Co. LTD | China | 61PIR74 TIRZEPATIDE (ANTI-DIABETIC) | NonSterile Powder | LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. INCONSPICU: Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. WARNINGS: It appears to lack adequate warning against use in a pathological condition or by children where it may be dangerous to health or against an unsafe dose, method, administering duration, application, in manner/form, to protect users. DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient. | XXX-0763336-3/1/2 |
| Oct 7, 2026 | XU LIHUA JINGFANG Trading Co. LTD | China | 61PIR72 SEMAGLUTIDE (ANTI-DIABETIC) | NonSterile Powder | LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. INCONSPICU: Information required by the Act to be on the label or labeling does not appear to be conspicuous enough as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. WARNINGS: It appears to lack adequate warning against use in a pathological condition or by children where it may be dangerous to health or against an unsafe dose, method, administering duration, application, in manner/form, to protect users. DRUG NAME: The article appears to be a drug and fails to bear the proprietary or established name and/or name and quantity of each active ingredient. | XXX-0763336-3/1/4 |
| Oct 2, 2026 | MetaTide Healthcare | Switzerland | 61PCK78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | XXX-0759691-4/1/1 |
| Sep 28, 2026 | Name not shown | China | 61PCR74 TIRZEPATIDE (ANTI-DIABETIC) | NonSterile Powder | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | XXX-0763136-5/1/1 |
| Sep 25, 2026 | Name not shown | United States | 61PDY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 1FX-2853870-1/10001/1 |
| Sep 24, 2026 | COMEM NATURAL JSC | Vietnam | 61PDZ78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 708NOREG A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act. 708LIST A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears to not be included in a list required by section 510(j). 708LBLFR A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears in a package form to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. | 1FX-2060079-8/20002/1D |
| Sep 24, 2026 | COMEM NATURAL JSC | Vietnam | 61PDZ78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 708NOREG A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act. 708LIST A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears to not be included in a list required by section 510(j). 708LBLFR A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears in a package form to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. | 1FX-2060079-8/20002/1H |
| Sep 24, 2026 | COMEM NATURAL JSC | Vietnam | 61PDZ78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 708NOREG A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act. 708LIST A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears to not be included in a list required by section 510(j). 708LBLFR A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears in a package form to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. | 1FX-2060079-8/20002/1I |
| Sep 22, 2026 | MITSUBISHI TANABE PHARMA CORPORATION . | Japan | 61PCP74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 1FX-8179469-5/10002/1 |
| Sep 18, 2026 | Name not shown | United States | 61PDY76 LIRAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | AEK-9731409-8/10001/1 |
| Sep 18, 2026 | Name not shown | United States | 61PDY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | AEK-9731409-8/20001/1 |
| Sep 14, 2026 | BIOAMINO LABS | Germany | 61PCZ74 TIRZEPATIDE (ANTI-DIABETIC) | Sterile Powder | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | XXX-0761571-4/1/1 |
| Sep 10, 2026 | ELI LILLY JAPAN | Japan | 61PCL74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | AEK-9702092-7/10002/1 |
| Sep 9, 2026 | Name not shown | France | 61PCY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | SCS-5013553-0/10003/1 |
| Sep 8, 2026 | Eli Lilly Italia SPA | Italy | 61PCY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | AEK-9744427-5/10002/1 |
| Sep 3, 2026 | Eli Lilly Japan K.K.Seishin Laboratories | Japan | 61PCK74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). NO ENGLISH: Required label or labeling appears to not be in English in violation of 21 C.F.R. 801.15(c)(1) FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | AEK-0976985-1/10002/1A |
| Sep 3, 2026 | Eli Lilly Japan K.K.Seishin Laboratories | Japan | 61PCK74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). NO ENGLISH: Required label or labeling appears to not be in English in violation of 21 C.F.R. 801.15(c)(1) FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | AEK-0976985-1/10002/1B |
| Sep 3, 2026 | Eli Lilly Japan K.K.Seishin Laboratories | Japan | 61PCK74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). NO ENGLISH: Required label or labeling appears to not be in English in violation of 21 C.F.R. 801.15(c)(1) FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | AEK-0976985-1/10002/1C |
| Aug 31, 2026 | NOVO NORDISK | Canada | 61PCL72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 708NEWDR A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears to be an unapproved new drug. | 799-1109746-0/10003/1 |
| Aug 31, 2026 | Eli Lillyand Company | United States | 61PCY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | AEK-0896550-0/10001/1 |
| Aug 25, 2026 | N EDGE GROUP INC | Canada | 61PCY78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 1FX-1683942-6/10002/1 |
| Aug 25, 2026 | N EDGE GROUP INC | Canada | 61PCY78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 1FX-1683962-4/10002/1 |
| Aug 25, 2026 | N EDGE GROUP INC | Canada | 61PCY78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 1FX-1684201-6/10002/1 |
| Aug 19, 2026 | MITSUBISHI TANABE PHARMA CORPORATION . | Japan | 61PCY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 1FX-8049552-6/10002/1 |
| Aug 18, 2026 | Novo Nordisk A/S | Denmark | 61PCP72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 9H5-0019713-6/10002/1 |
| Aug 14, 2026 | Novo Nordisk A/S | Denmark | 61PCK72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | AEK-0899165-4/10002/1 |
| Aug 14, 2026 | Eli Lilly & Company | United States | 61PCK74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | AEK-0899186-0/10002/1 |
| Aug 13, 2026 | Novo Nordisk A/S | Denmark | 61PCK72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). | 1FX-2262166-8/10002/1 |
| Aug 12, 2026 | Novo Nordisk A/S | Denmark | 61PCP72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 9H5-0019708-6/10002/1 |
| Jul 31, 2026 | Name not shown | Vietnam | 61PCY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | SCS-0349383-8/40002/2 |
| Jul 30, 2026 | Novo Nordisk A/S | Denmark | 61PCY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). | 1FX-3429534-5/10002/1 |
| Jul 27, 2026 | Eli Lilly Japan K.K.Seishin Laboratories | Japan | 61PDL74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | AEK-9601308-9/10002/1 |
| Jul 27, 2026 | Eli Lilly Japan K.K.Seishin Laboratories | Japan | 61PDL74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | AEK-9601308-9/10002/2 |
The 40 most recent are shown. Firm pages for the 67 business names are on the GLP-1 import records page; every line is in the CSV download. Names that do not read as a business are not shown.
Common questions
Are these all GLP-1 API shipments FDA refused?
They are the refused lines whose FDA product code description names semaglutide, tirzepatide, liraglutide, retatrutide or GLP-1. A shipment entered under another product code, such as a generic peptide code, is not counted.
Who is the declared manufacturer on a refused line?
The firm the importer named as manufacturer on the entry. The record does not say who shipped the goods, and a brand manufacturer’s name on a line does not mean that manufacturer shipped it.
Does a refusal mean FDA tested the product?
Only when the line says FDA sampled it: 2 of the 717 lines are marked for FDA sample analysis.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.